Business Wire

WEX ® Unlocks Access to 20,000+ Tesla Superchargers Across Europe

Share

WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform.

The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%.

WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: comparing real-time pricing across all networks, planning optimal routes, tracking sessions, and managing payments in one unified platform - regardless of the charging network they choose.

“Providing access to Tesla Superchargers through the WEX platform is a win for drivers and fleet managers,” said Jay Dearborn, WEX’s chief operating officer, International. “Drivers get effortless, reliable access to one of Europe’s largest fast-charging networks. Fleet managers gain the clarity and control they count on from WEX, with unified payments, smarter route planning, and more predictable charging costs. This update helps make EV operations simpler, more transparent, and ready for what’s next.”

How it works

Drivers have two flexible options to access Tesla Superchargers:

Via EV Driver by WEX: Select a Tesla Supercharger location and compare pricing with nearby alternatives. After selecting a connector, start a charging session from the app.

Via Tesla app: Add your WEX EV charge card as a payment method in the Tesla app and start a charging session there. Payments and billing remain in one place and are processed by WEX. Tesla drivers benefit from plug-and-charge convenience.

The integration is live now across all Tesla Supercharger locations for both Tesla and non-Tesla vehicles.

For more information on WEX EV charging options, please visit the WEX EV Solutions website.

About WEX

WEX (NYSE: WEX) is the global commerce platform that simplifies the business of running a business. WEX has created a powerful ecosystem that offers seamlessly embedded, personalized solutions for its customers around the world. Through its rich data and specialized expertise in simplifying benefits, reimagining mobility, and paying and getting paid, WEX aims to make it easy for companies to overcome complexity and reach their full potential. For more information, please visit www.wexinc.com.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, statements regarding WEX’s announced integration with the Tesla Supercharger network. Any statements in this press release that are not statements of historical facts are forward-looking statements. When used in this press release, the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “positions,” “confidence,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such words. Forward-looking statements relate to our future plans, objectives, expectations, and intentions and are not historical facts and accordingly involve known and unknown risks and uncertainties and other factors that may cause the actual results or performance to be materially different from future results or performance expressed or implied by these forward-looking statements, including the ability of the Company, its partners and its customers to realize the expected benefits from WEX’s integration with the Tesla Supercharger network; as well as other risks and uncertainties identified in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 20, 2025, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 1, 2025 and subsequent filings with the Securities and Exchange Commission. The forward-looking statements speak only as of the date of this press release and undue reliance should not be placed on these statements. The Company disclaims any obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251117575835/en/

Contacts

Media Contacts:
WEX
Johnston Farrow
+1 (832) 823-3044
johnston.farrow@wexinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff

Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 12:43:00 EET | Press release

Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf

Henlius and Organon Announce US FDA Approval of POHERDY ® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 12:30:00 EET | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds

Global Cement Industry Reports 25% CO 2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission17.11.2025 12:00:00 EET | Press release

The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/ GCCA Cement and Concrete Industry Net Zero Action and Progress Report The report finds that the industry has reduced the CO₂ intensity of cementitious products by 25% across the globe since 1990, and also sets out a series of policy recommendations that can pave the way for faster reductions. Dominik von Achten GCCA President and Chairman of the Managing Board of Heidelberg Materials said: "Our industry is collaborating and innovating across every aspect of our manufacturing – finding new ways to work and d

OpenAI and Capco Announce Services Partnership to Accelerate the Transformation of the Global Financial Services and Energy Sectors17.11.2025 12:00:00 EET | Press release

Global management and technology consultancy Capco, a Wipro company, has joined OpenAI’s Beta Services Partner Program, providing Capco with priority access to the very latest AI innovation. Capco and OpenAI will collaborate to solve complex client problems and deploy scalable solutions, positioning Capco as a trusted AI partner to financial services and energy clients worldwide. Through the services partnership, Capco gains early access to OpenAI’s technology, technical support, solution architects, and training resources. OpenAI will leverage Capco’s 25+ years of global transformation expertise and proven delivery experience across the financial services and energy sectors. Together, Capco and OpenAI will explore innovative solutions to tackle the most significant challenges confronting financial services and energy clients today. The opportunities for AI-led innovation are significant, ranging from enhanced product design to operational change and regulatory compliance, to employee

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye